C-CAMP signs agreement with Agilent to boost scientific advancements in biopharma

Bengaluru: The Centre for Cellular and Molecular Platform (C-CAMP) has signed an agreement with Agilent Technologies to pave the way for research and technology development in the sector of biosimilars and biopharmaceuticals, a core strength of both the organizations.

This agreement will primarily focus on mass spectrometry-based biotherapeutics/biosimilar characterization, a platform C-CAMP champions with its existing state-of-the art mass spectrometry facilities across proteomics, Metabolomics, lipidomics, glycomics, and biologics research.

Through this partnership, both organizations will leverage each other’s capabilities to hold joint training sessions and seminars for researchers across biopharma/ biosimilars start-ups and established companies. C-CAMP and Agilent will collaborate on product development and services for the biopharmaceutical industry, using the high-end scientific infrastructures and skill sets that both Agilent and C-CAMP share.

Upon signing the agreement, Dr. Taslimarif Saiyed, C-CAMP CEO & Director commented, “C-CAMP is steadily growing in the area of biopharmaceuticals and this partnership will greatly benefit the delivery of deep-science technologies to the biopharma sector. With this MoU, the start-ups associated with C-CAMP can easily access their high-end mass spectrometry solutions and technologies.”

Dr. Shirshendu Mukherjee, Mission Director, BIRAC congratulated both parties upon this agreement and said ‘Science should not be limited to only bench level research and at BIRAC we are proud to have worked closely with C-CAMP in scouting for cutting-edge scientific ideas, converting them to technologies and solving important challenges while also exploiting their commercial potential. This partnership is a win-win for both C-CAMP and Agilent as it will provide access to high-end technology platforms such as Agilent’s to researchers, innovators and startups during the crucial product development phase.”

Speaking on the value of this collaboration, Dr Samir Vyas, Agilent India Country General Manager said: “This is a unique collaboration in India where Agilent’s partnership has a greater vision to align with a flagship program named ‘Innovate in India (I3)’, enabling an ecosystem to promote entrepreneurship and manufacturing capabilities. This (I3) is an industry-academia mission to accelerate biopharmaceutical development in India and has been approved by the Government of India. With this, many of the upcoming and established biopharma start-ups would get opportunity to access the end-to- end biopharma workflow solutions from Agilent while leveraging on C-CAMP’s industry interface.”

C-CAMP facilitates bioscience research and innovation by providing training and services in addition to funding, incubation, and entrepreneurship development support. The organization is registered under the United States Food and Drug Administration (US FDA) to perform analyses towards active pharmaceutical ingredients, drug products, and drug substances. With Agilent’s support, C-CAMP will be catalyzing more research and development of biopharmaceuticals in compliance with global regulatory framework in India.